As reported by FDANews, the Safe Use Initiative is an important step toward lowering avoidable medication risks.
Since unavoidable medication risks—mostly represented by gaps in current medical knowledge—cannot be easily addressed by FDA, the agency's Safe Use Initiative focuses on avoidable medication risks which include the generation of erroneous prescriptions, information-related errors on the part of patients, process error due to the mistakes of medical professionals, accidental exposure (to children for example) of medication to individuals unaware of the drugs risk factors, issues of abuse/self-harm and drug defects. These aspects of avoidable medication risk can, according to the FDA and its recent report on drug safety and the Safe Use Initiative, be greatly improved via participation of the agency and relevant stakeholders.
For pharmaceutical industry professionals the Safe Use Initiative may result in more stringent quality standards such as increasingly strict REMs standards. To read more visit FDANews or the Washington Drug Letter.